HLS:CC News and Press, HLS Therapeutics Inc. From 11/07/22

HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at the American Heart Association Canada NewsWire Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular Risk Reduction Benefits of Eicosapentaen...

HLS Therapeutics to Host Q3 Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , Oct. 27, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2022 financial results o...

HLS Therapeutics Announces Updates to its Credit Agreement Canada NewsWire TORONTO , Oct. 3, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, an...

The S&P/TSX Composite Index was down 234 points in late-morning trading on Friday, September 16. This would represent the third triple-digit decline over this trading week. Some of the worst-performing sectors included health care, information technology, and industrials. Today,...

HLS Therapeutics to Participate in Virtual Non-Deal Roadshow on September 22, 2022 Canada NewsWire TORONTO , Sept. 15, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and c...

HLS Therapeutics Announces Q2 Fiscal 2022 Financial Results Canada NewsWire Q2 2022 revenue of $15.5 million , Adjusted EBITDA of $6.2 million and cash from operations of $3.5 million . Total Vascepa prescriptions grew 88% year-over-year, reflecti...

HLS announces that Vascepa® is now reimbursed by the Saskatchewan Drug Plan Canada NewsWire Reimbursement coverage for Vascepa in Canada is now approximately 70% for publicly covered lives and private coverage is now in excess of 95% for those that are in-la...

HLS Therapeutics to Host Q2 Fiscal 2022 Financial Results Conference Call Canada NewsWire TORONTO , July 28, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q2 Fiscal 2022 financial results o...

HLS Announces that Vascepa® is now reimbursed by Ontario's Provincial Drug Plan Canada NewsWire Reimbursement for Vascepa in Canada is now at more than 65% for publicly covered lives and private coverage is in excess of 95% for those who are in-label ...

HLS Therapeutics Obtains Public Reimbursement for Vascepa® in New Brunswick and with other Public Payors Canada NewsWire New Brunswick , Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will...